Uttar Pradesh: India’s Next Pharmaceutical Powerhouse

Uttar Pradesh: India’s Next Pharmaceutical Powerhouse

From policy to parks, research to execution, Uttar Pradesh is redefining the rules for pharmaceutical investment in India.

India is the pharmacy of the world—the third-largest pharmaceutical producer globally by volume, the largest supplier of generic medicines, and a major global source of active pharmaceutical ingredients. Its medicines reach over 200 countries. And within this national story, one state is rapidly emerging as the engine room: Uttar Pradesh.

Uttar Pradesh: A Story of Transformation

Today, Uttar Pradesh is a revenue-surplus and reform-driven economy. This change has been planned and clearly visible. In Ease of Doing Business rankings, the state moved up from 14th place in 2017–18 to 2nd in 2019–20. It was ranked an “Achiever State” in 2020–21, and then became a “Top Achiever State” in 2021–22 & 2023–24.

In Logistics Ease Across Different States (LEADS), it has been classified as an “Achiever State” consecutively from 2022 through 2024. The state ranked 1st in the Good Governance Index 2021 and 1st in Deregulation 1.0 in 2025.

These are not branding claims. They are independently verified, index-based rankings—hard data that reflects how Uttar Pradesh has fundamentally transformed the way it governs, regulates, and facilitates business.

India’s Largest Integrated Pharmaceutical Market

What separates Uttar Pradesh from every other pharma investment destination is not just its manufacturing potential—it is the convergence of production, consumption, and talent at a scale unmatched by any other state.

With a population of 25 crore, UP is India’s largest pharmaceutical consumer market—ensuring sustained, assured demand for manufacturers. This demand is served by one of the most extensive distribution networks in the country: over 81,000 wholesalers and more than 145,000 retail pharmacies, enabling efficient last-mile delivery across metros, smaller cities, and rural regions alike.

The state already hosts over 600 pharmaceutical manufacturers, offering scale, flexibility, and cost competitiveness across bulk drugs, formulations, and allied segments. With 9.6 million-plus MSMEs and a working-age population of 56%, UP’s manufacturing base is deep, diversified, and resilient.

“UP has more than 34 dedicated sectoral policies. Any investor coming to UP is facilitated through a single-window platform. If an investor has invested here in accordance with the policy, they receive their incentives on time, with strict accountability at every level.”

:- Hon’ble Chief Minister Yogi Adityanath at Pharma Conclave 1.0

Strategically Connected. Logistically Unmatched.

Infrastructure is where UP’s pharma ambitions become tangible. The state has built – not promised – a logistics and connectivity ecosystem that is genuinely unmatched among Indian states.

Uttar Pradesh accounts for 55% of India’s expressway network, with 22 expressways (7 operational, 15 under construction). It has the highest number of airports in any Indian state: 5 operational international airports (Lucknow, Ayodhya, Varanasi, Kushinagar and Noida International Airport at Jewar) along with 16 domestic airports. Metro rail is operational in 4 cities, with plans for 9 more. India’s first Rapid Rail Transit System—Namo Bharat—connects Delhi, Ghaziabad, and Meerut

For pharma and medtech supply chains specifically, UP sits at the intersection of the Eastern Dedicated Freight Corridor (57% coverage) and the Western Dedicated Freight Corridor (8.5% coverage), enabling direct freight linkage to Delhi-Mumbai and access to eastern ports for global trade.

Two Flagship Parks. One Pharmaceutical Ambition.

UP’s policy vision has been translated into concrete, shovel-ready real estate. Two flagship destinations anchor the state’s pharmaceutical manufacturing ecosystem:

Lalitpur Bulk Drug Pharma Park
1,472 acres

1. API & bulk drug manufacturing hub, plug-and-play infrastructure
2. Common utilities: solvent recovery, ETPs, quality power, 24×7 water
3. Within the Delhi–Mumbai Industrial Corridor influence zone
4. Hub-and-spoke model with integrated R&D capabilities
5. Proximity to Lalitpur Airstrip (~50 km), Jhansi Railway Junction (~50 km)

YEIDA–Jewar Medical Device Park
350 acres

1. Integrated MedTech manufacturing hub at the heart of NCR
2. Direct air cargo access via the upcoming Noida International Airport
3. High-value medical device, diagnostics & precision engineering
4. Expressway and DFC connectivity for global supply chains
5. Integration with NCR’s innovation and healthcare innovation ecosystem

Both parks are supported by special incentive packages under the UP Pharmaceutical and Medical Devices Policy 2023, including long-term interest subsidies, infrastructure support, and logistics incentives. They are designed as scalable, investor-centric ecosystems rather than industrial estates.

A Policy Stack Built for Every Stage of Investment

At the foundation of UP’s pharma investment case lies a robust, future-ready regulatory and incentive architecture. The UP Pharmaceutical and Medical Devices Policy, 2023, is the sector-specific framework. Alongside it, the Uttar Pradesh Industrial Investment & Employment Promotion Policy 2022, UP FDI/FCI, Fortune Global 500 & Fortune India 500 Companies Investment Promotion Policy 2023 and UP GCC Policy 2024 collectively provide one of the most comprehensive incentive stacks available to pharma investors in India.

Pharma Park Developer Incentives (Special Provision)

The "UP Model": Zero Interference, Time-Bound Delivery

Policy incentives are only as valuable as the governance that delivers them. This is where UP has decisively differentiated itself. The state’s Single Window platform, Nivesh Mitra, integrates approx. 225 services across 45+ departments, supported by 115+ dedicated Mukhyamantri Udyami Mitras—relationship managers who handhold investors from application to approval within 60 days.

UP ranks #1 in Deregulation Exercises 1.0 by implementing 100% across 23 priority and 71 sub-priority areas. Digital approvals now cover power, water, fire, and pollution. Minor offences have been decriminalised. Sector desks have been established for Textile, Auto & EV, Electronics, GCC, and Chemicals. Eight country desks — Germany, France, Taiwan, Singapore, South Korea, Japan, the UAE, and the UK — fast-track international investment.

Research, Talent & the Innovation Backbone

The pharmaceutical sector runs on science. UP’s research and institutional infrastructure—often underreported—makes it a genuine knowledge hub, not merely a manufacturing location.

The state hosts four national-level central laboratories, the Central Drug Research Institute (CDRI) and the National Botanical Research Institute (NBRI), both located in Lucknow. IIT Kanpur is home to a ₹1,200 crore MedTech Centre of Excellence, jointly supported by the state government and IIT Kanpur alums.

This initiative began with a ₹50 crore state commitment and has grown twelvefold. SGPGI Lucknow is being developed as a second Centre of Excellence. These are not proposals. They are functioning institutions.

The talent pipeline supporting this ecosystem is equally formidable. With 208+ medical and research institutes and 460+ pharmacy colleges, UP trains a continuous stream of pharma-ready professionals. This is augmented by a ₹2,000 crore UP AI Mission allocation, to be deployed over three years, specifically targeting AI integration in the medical and pharmaceutical sectors.

CDRI, Lucknow
Central Drug Research Institute—a national-level pharmaceutical research facility

NBRI, Lucknow
The National Botanical Research Institute has comprehensive drug discovery libraries.

IIT Kanpur MedTech CoE
₹1,200 crore centre of excellence in medical technology—state and alum-funded

SGPGI CoE
Sanjay Gandhi Post Graduate Institute (SGPGI), the second Centre of Excellence in development

4 Central Labs
Four national-level central laboratories are operational within the state.

UP AI Mission
₹2,000 crore over 3 years—including AI advancements in the pharma sector

UP Pharma Conclave 1.0: Execution, Not Celebration

On 3rd February, Lucknow hosted the inaugural UP Pharma Conclave 1.0, inaugurated by the Hon’ble Chief Minister Yogi Adityanath under the banner of Empowering Global Healthcare and organised by the Food Safety and Drug Administration, Uttar Pradesh (FSDA UP).

The gathering brought together the most prominent names from India’s pharmaceutical ecosystem: Dilip Shanghvi of Sun Pharma, Pankaj Patel of Zydus Lifesciences, Ramesh Juneja of Mankind Pharma, Satish Reddy of Dr Reddy’s Laboratories, Jinal Mehta of Torrent Pharma, and M.S.N. Reddy of MSN Laboratories, alongside NITI Aayog member Dr Vinod K. Paul and senior union government officials.

The conclave was not designed as a showcase. It was designed as a conversation about execution, with every session anchored in what UP has built, what is investable now, and how the state will deliver on its commitments.

Conclave 1.0: By the Numbers

₹10,000Cr+ Total MoUs Signed
Across bulk drugs, formulations, and medical devices – demonstrating diversified investor interest across the entire pharma value chain.

11 Companies Signed MoUs
Spanning pharmaceutical manufacturing, life sciences, and healthcare GCC segments

6+ Industry Giants Present
Including heads of Sun Pharma, Zydus, Mankind Pharma, Dr Reddy’s, Torrent Pharma, and MSN Laboratories

MoU Signatories at UP Pharma Conclave 1.0

1. Inva Pharma
2. BioZeta Life Sciences Pvt. Ltd.
3. Shukra Pharmaceuticals
4. Walter Bushnell Enterprises Pvt. Ltd.
5. Janvika Labs Pvt. Ltd.
6. CoroHealth GCC
7. Marc Laboratories
8. Hi-Glaze Laboratories
9. Raspa Pharma
10. Ram Sons Med World
11. Kotech Healthcare

Uttar Pradesh Is Ready to Lead India’s Next Pharma Chapter

India supplies medicines to over 200 countries. During the COVID-19 pandemic, the world saw, with clarity and relief, how indispensable India’s pharmaceutical sector truly is. What the world has not yet fully reckoned with is the role Uttar Pradesh is positioning itself to play in that story.

UP Pharma Conclave 1.0 was a milestone, not a finish line. It was a clear signal: the policy is in place, the infrastructure is ready, the governance is accountable, and the opportunity is open.

“UP is no longer a ‘BIMARU’ state. It has emerged as a breakthrough in the nation’s economy, operating as a revenue-surplus state ready to deploy whatever funds are necessary to build a conducive ecosystem for the pharma sector.”

:- Hon’ble Chief Minister Yogi Adityanath, UP Pharma Conclave 1.0